Condition
Advanced/Metastatic Breast Cancer
Total Trials
3
Recruiting
1
Active
1
Completed
1
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 5/100
Termination Rate
0.0%
0 terminated out of 3 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
33%
1 trials in Phase 3/4
Results Transparency
100%
1 of 1 completed with results
Key Signals
1 with results100% success
Data Visualizations
Phase Distribution
2Total
P 2 (1)
P 3 (1)
Trial Status
Recruiting1
Not Yet Recruiting1
Completed1
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (3)
Showing 3 of 3 trials
NCT07543536Phase 3Not Yet RecruitingPrimary
Megestrol Acetate for Fatigue Management in T-DXd Treated Breast Cancer
NCT02338167RecruitingPrimary
Praegnant Breast Cancer: Early/Advanced/Metastatic
NCT00662025Phase 2CompletedPrimary
Study Of Sunitinib With Capecitabine In Breast Cancer
Showing all 3 trials